Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Dec;57(1):2361745.
doi: 10.1080/08916934.2024.2361745. Epub 2024 Jun 8.

Animal models of immune-mediated demyelinating polyneuropathies

Affiliations
Review

Animal models of immune-mediated demyelinating polyneuropathies

Eroboghene E Ubogu. Autoimmunity. 2024 Dec.

Abstract

Immune-mediated demyelinating polyneuropathies (IMDPs) are rare disorders in which dysregulated adaptive immune responses cause peripheral nerve demyelinating inflammation and axonal injury in susceptible individuals. Despite significant advances in understanding IMDP pathogenesis guided by patient data and representative mammalian models, specific therapies are lacking. Significant knowledge gaps in IMDP pathogenesis still exist, e.g. precise antigen(s) and mechanisms that initially trigger immune system activation and identification of large population disease susceptibility factors. The initial directional cues for antigen-specific effector or autoreactive leukocyte trafficking into peripheral nerves are also unknown. An overview of current animal models, with emphasis on the experimental autoimmune neuritis and spontaneous autoimmune peripheral polyneuropathy models, is provided. Insights on the initial directional cues for peripheral nerve tissue specific autoimmunity using a novel Major Histocompatibility Complex class II conditional knockout mouse strain are also discussed, suggesting an essential research tool to study cell- and time-dependent adaptive immunity in autoimmune diseases.

Keywords: Acute inflammatory demyelinating polyradiculoneuropathy; animal models; blood-nerve barrier; chronic inflammatory demyelinating polyradiculoneuropathy; demyelinating neuritis; experimental autoimmune neuritis; major histocompatibility complex; mice; pathogenesis; spontaneous autoimmune peripheral polyneuropathy.

PubMed Disclaimer

References

    1. Wang L, Wang FS, Gershwin ME. Human autoimmune diseases: a comprehensive update. J Intern Med. 2015;278(4):369–95. Epub 2015/07/28. doi: 10.1111/joim.12395. - DOI - PubMed
    1. Miller FW. The increasing prevalence of autoimmunity and autoimmune diseases: an urgent call to action for improved understanding, diagnosis, treatment, and prevention. Curr Opin Immunol. 2023;80:102266. Epub 2022/11/30. doi: 10.1016/j.coi.2022.102266. - DOI - PMC - PubMed
    1. Liu S, Dong C, Ubogu EE. Immunotherapy of Guillain-Barre syndrome. Hum Vaccin Immunother. 2018;14(11):2568–79. Epub 2018/06/29. doi: 10.1080/21645515.2018.1493415. - DOI - PMC - PubMed
    1. Bragazzi NL, Kolahi AA, Nejadghaderi SA, Lochner P, Brigo F, Naldi A, et al. Global, regional, and national burden of Guillain-Barre syndrome and its underlying causes from 1990 to 2019. J Neuroinflammation. 2021;18(1):264. Epub 2021/11/13. doi: 10.1186/s12974-021-02319-4. - DOI - PMC - PubMed
    1. Frenzen PD. Economic cost of Guillain-Barre syndrome in the United States. Neurology. 2008;71(1):21–7. doi: 10.1212/01.wnl.0000316393.54258.d1. - DOI - PubMed

Publication types

Substances

LinkOut - more resources